Essi Viippola

Essi Viippola

Auto-generated profile, based on publicly available information

Essi Viippola

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
EVEssi Viippola
Essi Viippola
SKSara Kuitunen
Sara Kuitunen
RRRodosthenis S Rodosthenous
Rodosthenis S Rodosthenous
AVAndrius Vabalas
Andrius Vabalas
THTuomo Hartonen
Tuomo Hartonen
AGAndrea Ganna
Andrea Ganna
Nationwide health-related registry data provide comprehensive insights into population health and, combined with other data such as demographics, familial relations and socioeconomic data, enable the exploration of various dimensions of human behaviour and health. With the increasing size and variety of available data, advanced statistical and machine learning methods present novel possibilities for prediction and causal inference. 1–3 At the same time, efforts to extract high-quality ‘phenotypes’ from registries, for example clinical endpoints, are needed to provide interpretable results. In this spirit, projects such as the CALIBER initiative have provided curated phenotype definitions based on UK’s primary and secondary health care data. 4 Traditionally, the identification of risk factors and the creation of prediction models for diseases have been conducted using a targeted approach where a specific condition, risk factor or medication is studied for its association with a single disease. Several studies 4–10 have shown the potential of data-driven approaches in examining the associations of a large number of risk factors and thousands of disease trajectories. These studies have been accompanied by an increasing trend towards making the results publicly available through web portals, to enable the re-use of the results by other researchers.

8 July 2023 in Sage Open
Verified
Journal Article
Open access
MMMaisa Mielikäinen
Maisa Mielikäinen
EVEssi Viippola
Essi Viippola
Industry and higher education are increasingly utilizing online environments due to digitalization. As a result, the learning experiences in these new digital learning ecosystems as communities must be re-examined critically. This study incorporates the second cycle of the design-based research (DBR) study developing the design principles and theoretical framework for a digital learning ecosystem in Information and Communication Technology (ICT) engineering education in Lapland University of Applied Sciences (UAS), Finland. This cycle examines students’ learning experiences in a project and Industry 4.0-based approach in a digital learning ecosystem with authentic industry assignments and involvement. The study examines the learning experiences of ICT engineering students in a project and Industry 4.0-based approach in a digital environment with authentic industry assignments and involvement. The study was carried out using the Community of Inquiry (CoI) approach. Rasch Rating Scale Model was used to analyse first-, second-, and third-year students’ responses to a translated and adapted CoI questionnaire. Open-ended questions were added to the questionnaire, which was then analysed using content analysis. The results indicate that students perceived project-based learning in an online setting positively. However, the findings point to issues with social interactions and the actual application of learnt knowledge and skills. Challenges in task management and scheduling, as well as receiving feedback, had a somewhat negative impact on the learning experience, particularly during the first year of study. Finally, this paper concludes by presenting a visual model summarizing the design framework developed through a broader DBR study informed by the previous DBR cycles. The findings may benefit practitioners in developing similar communities and ecosystems.

15 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DFDaniela Fusco
Daniela Fusco
ZYZhijian Yang
Zhijian Yang
EVEssi Viippola
Essi Viippola
TCTatiana Cajuso
Tatiana Cajuso
ACAndrea Corbetta
Andrea Corbetta
AGAndrea Ganna
Andrea Ganna
Plasma protein levels are influenced by both genetic and non-genetic factors and can serve as early disease biomarkers. When a protein is correlated with, but not causally linked to, disease, its genetic determinants can add unwanted variability to protein–disease associations. In such cases, removing the genetic component may improve their predictive performances. Here, we tested this hypothesis by genetically adjusting 94 highly heritable proteins spanning diverse biological pathways and evaluating their associations with the onset of 37 diseases in 39,871 UK Biobank participants. Genetically adjusted proteins showed stronger associations in 88% of 1,312 significant protein–disease pairs, equivalent to a 30% median reduction in required sample size for comparable power. Of 96 protein–disease pairs with significant differences, all but one showed larger effects for adjusted proteins. Most proteins also showed consistently stronger associations with environmental and lifestyle factors once genetic effects were removed. Finally, we constructed multi-protein scores from genetically adjusted proteins and demonstrated that they significantly improve prediction for 7 diseases compared to unadjusted proteins. These findings demonstrate that removing genetic effects from plasma proteins is an effective strategy to increase power for biomarker discovery and clinical trial design, consistent with the largely non-causal role of most plasma proteins in disease risk.

21 October 2026
Verified
Preprint
Open access
PDF file
EVEssi Viippola
Essi Viippola
THTuomo Hartonen
Tuomo Hartonen
MZMeihui Zhu
Meihui Zhu
ZYZhijian Yang
Zhijian Yang
RERyuya Edahiro
Ryuya Edahiro
AGAndrea Ganna
Andrea Ganna
Sex differences in human health are typically modeled as binary comparisons between males (XY) and females (XX). However, sex-linked molecular traits vary continuously and are shaped by environmental factors. Here, we introduce the Proteomic Sex Index (PSI), a continuous, plasma proteomics–based measure that quantifies the degree to which an individual’s proteome aligns with their chromosomal sex, with higher PSI values indicating profiles less typical for their sex. Leveraging data from 51,310 individuals from six demographically heterogeneous cohorts, we show that PSI captures broad, biologically meaningful variation in sex-enriched traits and diseases. Individuals with proteomic profiles shifted away from their chromosomal sex exhibited trait values less characteristic of that sex. For example, males with higher PSI were shorter, had lower grip strength, and showed reduced severity of COVID-19 (OR=0.59, p =3.0×10 −7 ). Analyses of individuals undergoing gender-affirming hormone therapy showed that, although PSI correlated with circulating sex hormones, it also captured additional variation independent of hormone levels. PSI is partially heritable and genetically influenced. Individuals with Klinefelter syndrome (XXY) had markedly elevated PSI (OR=13.7, p =1.1×10 −13 ), and genome-wide association studies of PSI identified sex-biased cis-pQTLs with evidence of causal links to sex-specific disease risk. PSI provides a nuanced, individualized measure of sex-related biology that enables the study of within-sex molecular variation and its links to health and disease.

7 September 2026 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
PVPekka Vartiainen
Pekka Vartiainen
HHHele Haapaniemi
Hele Haapaniemi
YLYunsung Lee
Yunsung Lee
MMMaria C. Magnus
Maria C. Magnus
THTuomo Hartonen
Tuomo Hartonen
SHSanttu Heinonen
Santtu Heinonen

24 February 2023 in medRxiv
Verified
Preprint
Open access
PDF file
PVPekka Vartiainen
Pekka Vartiainen
SJSakari Jukarainen
Sakari Jukarainen
SRSamuel Arthur Rhedin
Samuel Arthur Rhedin
APAlexandra Prinz
Alexandra Prinz
THTuomo Hartonen
Tuomo Hartonen
AGAndrea Ganna
Andrea Ganna
Background Novel immunisation methods against respiratory syncytial virus (RSV) are emerging, but knowledge of risk factors for severe RSV disease is insufficient for their optimal targeting. We aimed to identify predictors for RSV hospitalisation, and to develop and validate a clinical prediction model to guide RSV immunoprophylaxis for under 1-year-old infants. Methods In this retrospective cohort study using nationwide registries, we studied all infants born in 1997-2020 in Finland (n = 1 254 913) and in 2006-2020 in Sweden (n = 1 459 472), and their parents and siblings. We screened 1 510 candidate predictors and we created a logistic regression model with 16 predictors and compared its performance to a machine learning model (XGboost) using all 1 510 candidate predictors. Findings In addition to known predictors such as severe congenital heart defects (CHD, adjusted odds ratio (aOR) 2·89, 95% confidence interval 2·28-3·65), we identified novel predictors for RSVH, most notably esophageal malformations (aOR 3·11, 1·86-5·19) and lower complexity CHDs (aOR 1·43, 1·25-1·63). In validation data from 2018-2020, the C-statistic was 0·766 (0·742-0·789) in Finland and 0·737 (0·710-0·762) in Sweden. The clinical prediction model’s performance was similar to the machine learning model (C-statistic in Finland 0·771, 0·754-0·788). Calibration varied according to epidemic intensity. Model performance was similar across different strata of parental income. The infants in the 90th percentile of predicted RSVH probability hospitalisation had 3·3 times higher observed risk than the population’s average. Assuming 60% effectiveness, immunisation in this top 10% of infants at highest risk would have a number needed to treat of 23 in Finland and 40 in Sweden in preventing hospitalisations. Interpretation The identified predictors and the prediction model can be used in guiding RSV immunoprophylaxis in infants. Funding Sigrid Jusélius Foundation, European Research Council, Pediatric Research Foundation (for complete list of funding sources, see Acknowledgements).